Journal article Open Access

Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.

Ooms, Maarten; Rietjens, Roma; Rangarajan, Janaki Raman; Vunckx, Kathleen; Valdeolivas, Sara; Maes, Frederik; Himmelreich, Uwe; Fernandez-Ruiz, Javier; Bormans, Guy; Van Laere, Koen; Casteels, Cindy

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Ooms, Maarten</dc:creator>
  <dc:creator>Rietjens, Roma</dc:creator>
  <dc:creator>Rangarajan, Janaki Raman</dc:creator>
  <dc:creator>Vunckx, Kathleen</dc:creator>
  <dc:creator>Valdeolivas, Sara</dc:creator>
  <dc:creator>Maes, Frederik</dc:creator>
  <dc:creator>Himmelreich, Uwe</dc:creator>
  <dc:creator>Fernandez-Ruiz, Javier</dc:creator>
  <dc:creator>Bormans, Guy</dc:creator>
  <dc:creator>Van Laere, Koen</dc:creator>
  <dc:creator>Casteels, Cindy</dc:creator>
  <dc:description>Purpose: Several lines of evidence imply early alterations in endocannabinoid and phosphodiesterase 10A (PDE10A) signaling in Huntington disease (HD). Using [18F]MK-9470 and [18F]JNJ42259152 small-animal PET, we investigated for the first time cerebral changes in type 1 cannabinoid (CB1) receptor binding and PDE10A levels in vivo in pre-, early- and late symptomatic HD (R6/2) mice, in relation to glucose metabolism ([18F]FDG PET), brain morphology (MRI) and motor function. 

Methods: Ten R6/2 and 16 wild-type (WT) mice were investigated at 3 different time points between the age of 4 and 13 weeks. Parametric CB1 receptor and PDE10A images were anatomically standardized to Paxinos space and analyzed voxel-wise. Volumetric microMRI imaging was performed to assess HD pathology. 

Results: In R6/2 mice, CB1 receptor binding was decreased in comparison to WT in a cluster comprising the bilateral caudate-putamen, globus pallidus and thalamic nucleus at week 5 (-8.1±2.6%; p=1.7.10-5). Longitudinal follow-up showed further progressive decline compared to controls in a cluster comprising the bilateral hippocampus, caudate-putamen, globus pallidus, superior colliculus, thalamic nucleus and cerebellum (late vs. presymptomatic age: -13.7±3.1% for R6/2 and +1.5±4.0% for WT; p=1.9.10-5). In R6/2 mice, PDE10A binding potential also decreased over time, to reach significance at early and late symptomatic HD (late vs. presymptomatic age: -79.1±1.9% for R6/2 and +2.1±2.7% for WT; p=1.5.10-4). The observed changes in CB1 receptor and PDE10A binding were correlated to anomalies exhibited by R6/2 animals in motor function, while no correlation was found with MRI-based striatal volume. 

Conclusion: Our findings point to early regional dysfunctions in endocannabinoid and PDE10A signaling, involving the caudate-putamen and lateral globus pallidus, that may play a role in the progression of the disease in R6/2 animals. PET quantification of in vivo CB1 and/or PDE10A binding may thus be useful early biomarkers for HD. Our results also provide evidence of subtle motor deficits at earlier stages than previously described.</dc:description>
  <dc:source>Neurobiol Aging.  35(12) 2858-69 (2014)</dc:source>
  <dc:subject>Type 1 cannabinoid receptor, ,, , </dc:subject>
  <dc:subject>phosphodiesterase 10A</dc:subject>
  <dc:subject> Huntington disease</dc:subject>
  <dc:subject>small-animal PET</dc:subject>
  <dc:subject>R6/2 mice</dc:subject>
  <dc:title>Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.</dc:title>
Views 44
Downloads 61
Data volume 334.9 MB
Unique views 44
Unique downloads 61


Cite as